Urinary sulphated glycosaminoglycans excretion in obese patients with type 2 diabetes mellitus treated with metformin.

Abstract

OBJECTIVE:

The pattern of urinary excretion of total sulphated glycosaminoglycans (GAGs) and their particular types: chondroitin sulphate/dermatan sulphate (CS/DS) and heparan sulphate (HS) was analysed in obese patients with type 2 diabetes mellitus (T2DM) treated with metformin in monotherapy for the period of six months.

METHODS:

The urinary sulphated glycosaminoglycans were quantitated using standardised dye (1.9-dimethylmethylene blue)-binding method and normalised to creatinine level.

RESULTS:

Urinary total GAGs, CS/DS and HS levels were significantly higher in untreated diabetic patients in comparison to healthy subjects. Moreover, it was observed that urinary total GAGs, CS/DS and HS levels in diabetic patients after six-month metformin therapy were significantly decreased versus pre-treatment situation.

CONCLUSIONS:

The obtained results suggest that the six-month treatment with metformin in obese patients with T2DM has a regulating influence on the systemic changes in proteoglycans/glycosaminoglycans, resulting in a decrease in the urinary excretion of total GAGs, CS/DS and HS.

• Authors: Agnieszka Jura-Półtorak, Paweł Olczyk, Aleksandra Chałas-Lipka, Katarzyna Komosińska-Vassev, Kornelia Kuźnik-Trocha, Katarzyna Winsz-Szczotka, Diana Ivanova, Yoana Kiselova-Kaneva, Katarzyna Krysik, Alicja Telega, Krystyna Olczyk
• Journal: Archives of physiology and biochemistry (Arch Physiol Biochem) Vol. 128 Issue 2 Pg. 507-513 (Apr 2022) ISSN: 1744-4160 [Electronic] England
• PMID: 31815550 (Publication Type: Journal Article)

Chemical References

• Glycosaminoglycans
• A73025
• Metformin

Topics

• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Glycosaminoglycans (urine)
• Humans
• Metformin (therapeutic use)
• Obesity (complications)